Coronary Microvascular Disease in Chronic Chagas Cardiomyopathy Including an Overview on History, Pathology, and Other Proposed Pathogenic Mechanisms by Rossi, Marcos A. et al.
Review
Coronary Microvascular Disease in Chronic Chagas
Cardiomyopathy Including an Overview on History,
Pathology, and Other Proposed Pathogenic Mechanisms
Marcos A. Rossi
1*, Herbert B. Tanowitz
2, Lygia M. Malvestio
1, Mara R. Celes
1, Erica C. Campos
1, Valdecir
Blefari
1, Cibele M. Prado
1
1Department of Pathology, Laboratory of Cellular and Molecular Cardiology, Faculty of Medicine of Ribeira ˜o Preto, University of Sa ˜o Paulo, Ribeira ˜o Preto, Sa ˜o Paulo,
Brazil, 2Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America
Abstract: This review focuses on the short and bewil-
dered history of Brazilian scientist Carlos Chagas’s
discovery and subsequent developments, the anatomo-
pathological features of chronic Chagas cardiomyopathy
(CCC), an overview on the controversies surrounding
theories concerning its pathogenesis, and studies that
support the microvascular hypothesis to further explain
the pathological features and clinical course of CCC. It is
our belief that knowledge of this particular and remark-
able cardiomyopathy will shed light not only on the
microvascular involvement of its pathogenesis, but also
on the pathogenetic processes of other cardiomyopa-
thies, which will hopefully provide a better understanding
of the various changes that may lead to an end-stage
heart disease with similar features. This review is written
to celebrate the 100th anniversary of the discovery of
Chagas disease.
Introduction
Abnormalities of microcirculation have been demonstrated in
several different cardiomyopathies [1,2], and microvascular spasm
was proposed as a common pathogenic mechanism for the
development of the characteristic focal myocytolytic necrosis in
these cardiomyopathies [3–6].
We suggested that alterations in the microvasculature contrib-
uted to the pathogenesis of experimental chronic Chagas
cardiomyopathy (CCC) [7,8]. Mice infected with Trypanosoma cruzi
(T. cruzi) developed a chronic cardiomyopathy similar to that
observed in the chronic phase of Chagas disease in humans.
Aggregated platelets forming transient occlusive thrombi were
found in small epicardial and intramyocardial vessels associated
with foci of myocytolytic necrosis and degeneration with an
inflammatory mononuclear infiltrate and interstitial fibrosis. Soon
afterwards, areas of focal vascular constrictions, microaneurysm
formation, and dilatation were demonstrated in mice acutely
infected with T. cruzi [9]. In 1990, we proposed the participation of
microcirculation via transient ischemia in the pathogenesis of
CCC [10]. At that time, two hypotheses regarding the pathogen-
esis of CCC were being intensely investigated: parasympathetic
intrinsic denervation as the mechanism of cardioneuropathy
[11–13] and the participation of autoimmune mechanisms in the
genesis of chronic fibrosing myocarditis [14–16].
This review focuses on the short and bewildered history of
Chagas’s discovery and subsequent developments, the anatomo-
pathological features of CCC, an overview of the controversies
surrounding theories concerning the pathogenesis of CCC, and
studies that support the microvascular hypothesis that further
explains the pathology and clinical course of CCC. It is our belief
that knowledge of this particular and remarkable cardiomyopathy
will shed light not only on the microvascular involvement of its
pathogenesis, but also on the pathogenetic processes of other
cardiomyopathies, which will hopefully provide a better under-
standing of the various changes that may lead to an end-stage
heart disease with similar features. As stressed by Factor [17], ‘‘…
the similarity of Chagas disease to other dilated congestive
cardiomyopathies, particularly those due to viral etiology, should
make awareness of the South and Central American disease
relevant to investigators outside endemic areas’’. Moreover, as a
consequence of increased global migration due to socioeconomic
reasons and facilitated by international travel, Chagas disease may
expand exponentially from rural and endemic areas to urban and
nonendemic areas, respectively. Furthermore, this review marks
the 100th anniversary of the discovery of the disease by the
Brazilian scientist Carlos Chagas. Simultaneously, 2009 marked a
hundred years of negligence concerning Chagas disease, which is
endemic in the most impoverished populations in Latin America
that are still living in poor quality housing with substandard
conditions, i.e., the primary habitat for T. cruzi vectors and mode
of transmission besides blood transfusion, oral, and congenital T.
cruzi infection transmission.
Carlos Chagas’s Discovery
In 1908, the Brazilian government, when building a railroad
from Rio de Janeiro (the capital of Brazil at the time) to Belem (in
the north of the Amazon Basin), a task that was never completed,
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Janeiro, because of a severe malaria outbreak involving the
railroad workers [11,18,19]. Oswaldo Cruz, director of Manguin-
hos Institute in Rio de Janeiro (currently known as Oswaldo Cruz
Institute), commissioned Carlos Chagas and Belisario Pena to that
region in an attempt to control the outbreak. They settled their
headquarters in Lassance in a railroad car, which served as the
consultation room, laboratory, and quarters. After one year of
intensive work, Chagas was told by a railroad engineer about the
existence of hematophagous bugs, which were known as
‘‘barbeiros’’ (barbers) or ‘‘kissing bugs’’ due to their typical
behavior of biting sleeping human beings at night on the
uncovered face. Chagas became interested in investigating the
possibility of this bug transmitting parasites to humans or other
vertebrates. He soon detected flagellates resembling crithidiae in
the bugs’ hindgut. Intrigued by the possibility that this parasite
could represent an evolutionary stage of Trypanosoma minasense,
which he had previously described infesting marmosets, he sent
some bugs to Manguinhos to be fed to primates that were free of
infection. After some weeks, the same flagellates seen in the
hindgut of the bugs were recovered from the bloodstream of the
animals, and a new species different from T. minasense or ‘‘any
other species of the same genus’’ was recognized. The parasite was
first named as Schyzotrypanum cruzi in honor of Oswaldo Cruz, but it
was subsequently renamed Trypanosoma cruzi.
Chagas returned to Lassance looking for the presence of
vertebrate hosts of this newly discovered parasite. After several
tests in humans and animals, he found a cat with parasites in the
bloodstream. A few weeks later, he was asked to investigate the
possibility of an acute malarial episode in a two-year-old girl
named Berenice living in the same house where the cat was found.
He had clinically examined this girl before and now parasites were
detected in the blood, suggesting the acute phase of a new disease.
Further examinations demonstrated that the flagellates disap-
peared as the symptoms vanished, thus raising the possibility of a
chronic phase of the new disease. On April 15, 1909, Oswaldo
Cruz reported Chagas’s discovery to the Brazilian National
Academy of Medicine. A complete study on the evolutive cycle
of the T. cruzi was published in the first volume of the Maguinhos
Institute journal, Memo ´rias do Instituto Oswaldo Cruz, in August 1909
[20]. On October 26 of the same year, Chagas presented his first
lecture on American trypanosomiasis in the Brazilian National
Academy of Medicine, calling his discovery ‘‘a new realm in
Pathology’’. The genius of Carlos Chagas enabled him to describe
the agent, vectors, and main mechanism of disease transmission,
clinical signs in humans and animals, and the existence of animal
reservoirs. The merit of his research, the circumstances surround-
ing it, and the subsequent development of the field represent one
of the most important pages in the history of medical science.
Never before or since has a single scientist, a clinician and clinical
investigator, fully characterized a new disease in all its aspects in
this manner.
After some time, this important discovery by Chagas resulted in
violent arguments and also led to denials, probably because it was
beyond the comprehension of many of the physicians and scientists
of those days and because his contemporaries envied him. In 1915,
the campaign directed against Chagas intensified when Kraus, a
German bacteriologist from the Buenos Aires Bacteriology
Institute in Argentina, could not find any human cases of Chagas
disease in northern Argentina, although a great number of infected
bugs were found in hut dwellings. Chagas rejected Kraus’s report,
but the attacks and doubts against his discovery continued, and he
was called ‘‘a man who searches in the jungle for diseases which do
not exist’’. After 1920, Chagas disease was simply forgotten and
disappeared from nosology as an infectious disease of public health
importance. The rediscovery of Chagas disease was made by
Salvador Mazza, an Argentine physician, in 1934, just before
Chagas’s death, on November 8 of that year. He reported many
acute cases found in northern Argentina, exactly where Kraus
failed to find any human case of the disease. Like Chagas, Mazza
was criticized for ‘‘discovering new diseases instead of treating the
many already existing ones’’. Due to Mazza’s research, investiga-
tions on once forgotten Chagas disease were reinstated in South
America, now recognized just as a cardiopathy. Only two decades
later, the now well-known late manifestations of Chagas disease
mega-syndromes, usually megaesophagus and megacolon, conjec-
tured by Chagas [21], in which the pathogenic mechanism is the
intrinsic denervation of the viscera, were only recognized as of
chagasic etiology through the works of Ko ¨berle [22], an Austrian-
born pathologist, founder of the Department of Pathology of the
Faculty of Medicine of Ribeira ˜o Preto, University of Sa ˜o Paulo. In
his thesis for the position of full professor, Ko ¨berle states that ‘‘…
The knowledge of the high incidence of Chagas disease in
Ribeira ˜o Preto and surroundings, associated with the verification
of a large number of megas in the same region, led us to
suspect of the chagasic etiology of the megas in Brazil and to
study its pathogenic mechanism, particularly that of the
megaesophagus ….’’
Pathology of Chronic Chagas Cardiomyopathy
By the early 1990s, the World Health Organization (WHO)
considered Chagas disease the most serious parasitic disease in
Latin America [23] and as having the greatest economic impact.
The number of estimated infected people was approximately 18
million, with a further 100 million under risk. Now, the revised
numbers are much reduced, with an estimate of about 10–13
million [24] or, even less, 8–10 million infected people [25,26].
Large-scale local initiatives to halt vector-borne transmission
together with the improvement of blood-donor screening tests to
control blood transfusion and congenital T. cruzi infection
transmission, such as the ‘‘Southern Cone Initiative’’, explain
most of this success [27]. Notwithstanding, Chagas disease is still
classified as one of the most neglected diseases in the world [28],
since there are still 200,000 new cases of Chagas disease notified
each year and some rural communities in Latin America with
seroprevalence rates as high as 40% [29]. Although primary
infection continues to endanger the lives of countless people in
Latin America, the real challenge concerning the millions of
chronic chagasic patients is the control and treatment of the
chronic manifestations of the disease. For this it is essential to
understand the pathogenesis of the late manifestations of the
disease.
Chagas disease is characterized by three phases: acute,
indeterminate or latent, and chronic. The heart is the most
severely and frequently involved organ. The cardiac involvement
during the acute phase varies from mild (asymptomatic or
olygosymptomatic) to severe. The latter may be fatal, occurring
in 3%–5% of cases. The indeterminate or latent phase, between
the acute and chronic phases, usually of long duration (up to 10–
30 years), is characterized by the absence of clinicopathological
evidence and is usually accompanied by either a normal
electrocardiogram or one with minor disturbances of cardiac
rhythm. Approximately 30% of the infected individuals eventually
develop late manifestations. The symptomatic disease affects the
heart in 94.5% of patients that are considered to have CCC,
usually between 15 and 50 years of age. Congestive heart failure is
the cause of death in 58% of these patients, whereas cardiac
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manifests as mega-syndromes of hollow viscera, usually mega-
esophagus and megacolon.
Three stages are seen in CCC. In the initial stage the patient has
a few symptoms, usually related to disturbances of rhythm. In the
intermediate stage the clinical signs usually correlate with a mildly
to moderately enlarged heart. In the final stage, the most
significant clinical manifestation includes congestive heart failure,
thromboembolic phenomena, severe arrhythmias, and sudden
death [11,30–33]. Alterations in cardiac function, severe conduc-
tion abnormalities, and episodes of ventricular arrhythmias or
syncope are considered to predispose chagasic patients to sudden
unexpected death, a significant risk at any stage of the disease
[11,33,34].
The main pathological changes reflect the importance of the
involvement of the heart in Chagas disease [11,18,30,33,35]. In
the acute phase, the heart is globular and flabby. Foci of
myocytolytic necrosis and degeneration are observed microscop-
ically with an intense mononuclear inflammatory infiltrate and
intense parasitism of myofibers (Figure 1A). Most of the hearts
with CCC show a marked alteration in size and form, although
some hearts appear to be normal in size and form (Figure 2). All
degrees of enlargement of the heart may be found, mainly
affecting the right-sided chambers of the heart, with dilatation
being more pronounced than hypertrophy. More than 50% of
chagasic hearts show a peculiar lesion of the apex of the heart,
mainly the left ventricle apex, consisting of thinning and bulging of
the apical region, the so-called apical aneurysm. Similar localized
parietal thinning may occur in the left and right ventricular free
walls. Fibroadipose or adipose replacement of the right ventricular
myocardium, particularly at the apical area of the right ventricle,
may be observed, occasionally associated with a bulging of the
apex. This attenuation of the myocardium implicates mainly the
apical region, although the entire right ventricular free wall can be
involved. Thrombosis of the aneurysm is common. Even without
aneurysm, extensive mural thombosis in the lower part of the left
ventricle and in the dilated right auricle may be seen [36]. The
presence of thrombi explains the frequent occurrence of
thromboembolic phenomena in the pulmonary and systemic
circulation. In CCC, micropathology reveals focal and diffuse
chronic fibrosing myocarditis (Figure 1C and 1D). Diffuse foci of
myocardial micronecrosis are present and associated with an
inflammatory infiltrate composed predominantly of lymphomono-
nuclear cells and interstitial fibrosis, one of the most prominent
features (Figure 1B) [37–40]. This remodeling of the collagenous
matrix leads to progressive myocardial decompensation by
decreased cardiac output, combined with an increased workload
due to myocardial stiffness. The conduction system shows
inflammatory and fibrotic lesions similar to those found in the
myocardium [34,41]. Myofibers containing parasites are virtually
never found in the chronic phase of the disease. Destruction of the
intrinsic cardiac and enteric nervous system (chiefly parasympa-
thetic ganglion cells) and mediastinal paraganglia has been
demonstrated [11,42,43].
Theories on the Pathogenesis of CCC
The pathogenesis of chronic chagasic cardiopathy is still not
fully understood. Different mechanisms have been proposed.
Direct Tissue Destruction by Trypanosoma cruzi
The existence of different clinical forms of the disease was soon
identified, which was at first thought to be associated with
differences in the parasites implicated. Indeed, even Chagas
noticed a peculiar dimorphism, the so-called slender and stout
forms of the parasite in the bloodstream, observations later
confirmed by many others [44,45]. Today, these two morpholog-
ical forms are believed to emerge from epigenetic phenomena and
their pathological relevance is obscure [46]. At a very early stage,
the idea of a major role of differential tissue tropism in the
pathogenesis of Chagas disease was proposed [47,48]. This idea
has persisted in spite of only tenuous evidence based mainly on the
parasite distribution in different tissues in the acute phase of
experimentally infected animals [49–51].
In chronic Chagas disease, parasites are rarely found in tissues
examined by routine techniques [11,52]. However, parasite
antigens were disclosed in the myocardial tissue by application
of immunohistochemical techniques [53] and sensitive polymerase
chain reaction (PCR) [54–56]. These observations support a role
for persistent antigenic stimulation throughout the chronic phase
in the pathogenesis of myocardial changes. New studies may
highlight the primary role of T. cruzi in the pathogenesis of Chagas
disease and set the stage for establishing the notion that genomic
variation of T. cruzi might influence the course of the disease.
Autonomic Abnormalities
The autonomic nervous system of patients with Chagas disease
has been extensively studied [11,13]. CCC could be a neurogenic
form of heart disease promoted by the destruction of the
parasympathetic ganglions cells in the heart. Early morphological
investigations revealed a conspicuous reduction in the number of
cardiac parasympathetic neurons of patients who had died from
intractable congestive heart failure. The extent of heart denerva-
tion seen in Chagas disease has not been detected in any other
cardiopathy so far studied, though a number of cardioneuropa-
thies have been described [57]. Abnormalities of autonomic heart
rate control were also described in clinical studies of asymptomatic
patients with cardiac enlargement on chest X-rays [58,59].
Malignant ventricular tachyarrhythmias (ventricular tachycardia,
ventricular fibrillation) are major causes of sudden death among
patients with CCC. The destruction of the parasympathetic
innervation could induce an increased sympathetic tone with
either a direct effect in arrhythmogenesis via altering the
electrophysiologic properties of the heart or an indirect effect via
other mechanisms, such as increased oxygen demand by
catecholamines, increased coronary vasomotor tone, and aug-
mented platelet adhesiveness [60]. It is now well established that
the intrinsic denervation of organs occurs in the acute phase of the
disease because of IFN-c-elicited nitric oxide (NO) production
resulting from inducible nitric oxide synthase (iNOS) activation of
the inflammatory foci [43]. The main dilemma of the neurogenic
theory remains in the uncertainty about its physiopathologic
mechanism, i.e., its implication in the pathogenesis of the chronic
fibrosing myocarditis.
Role of Autoimmune Mechanisms
The participation of autoimmune mechanisms in the genesis of
the chronic myocarditis of Chagas disease has been postulated
[14–16]. The relative lack of parasites in the myocardium during
the chronic phase was the origin of many autoimmune theories,
including both a humoral and cellular origin. The establishment of
an organ-specific autoimmune nature for Chagas disease chronic
fibrosing myocarditis has been waiting on an experimental model
that could provide evidence in support of the hypothesis and allow
specific manipulations by which different sets of lymphocytes could
be implicated in the generation of the disease. Perhaps the most
compelling evidence supporting the role for autoimmunity comes
from the demonstration that anti-CD4 abrogates rejection and
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grafted in mice chronically infected with T. cruzi [61], although
this does not happen when different strains of parasites and mice
are employed [62].
Two criticisms are often used against the hypothesis that CCC is
an autoimmune disease. The first is that immunosuppressants,
which generally relieve symptoms of autoimmune diseases,
exacerbate mortality in individuals with Chagas disease, and the
second is that therapy directed at the parasite often ameliorates the
clinical disease in humans and experimental animals [63].
It has been assumed that autoimmunity is triggered after the
initial contact with the parasite and that immunological processes
continue during the chronic phase of the disease [64]. This,
however, has not been proven. Most of the inference on the
alleged immunological mechanisms implicated in the chronic
phase of cardiac disease pathogenesis, when rarely a parasitic
pseudocyst can be detected, is based on experiments with animals
acutely infected with T. cruzi in which the acute myocarditis is
directly related to the presence of the parasite.
Studies Involving Microcirculation and Chagas Disease
Studies in mice and rats. In mice first immunized with
several inoculations with epimastigote forms of the avirulent PF
strain of T. cruzi and then challenged with trypomastigotes of the
virulent Colombian strain of T. cruzi, isogenic BALB/c mice
developed a cardiomyopathy very similar to that observed in the
chronic phase of human Chagas disease [7]. Macroscopically,
there was cardiomegaly with hypertrophy and dilatation of the
ventricular chambers associated with thinning of the left ventricle
apex in 46% of the hearts (apical aneurysm) (Figure 3A). The
microscopic findings revealed focal areas of myocytolytic necrosis
and myocardial degeneration associated with a lymphomo-
nonuclear inflammatory infiltrate accompanied by interstitial
fibrosis and occasional pseudocysts. In addition, platelet
aggregates, forming transient occlusive thrombi, were detected in
small epicardial and intramyocardial vessels, direct evidence of
microcirculatory disease (Figures 3B and 3D). Moreover, the focal
nature of the myocardial lesion and the type of myonecrosis
represent the indirect evidence for the involvement of the
microcirculation in this model (Figure 3C). The release of
vasoconstrictor substances, such as thromboxane A2 (TXA2) and
platelet activating factor (PAF) by macrophages, which are the
predominant inflammatory cells, was proposed to cause transient
ischemia and myocytolytic necrosis [8].
A/J mice infected with the Brazil strain and perfused with
silicone rubber (Microfil) 15–17 days post-infection revealed
numerous areas of focal vascular constriction, microaneurysm
formation, dilatation, and proliferation of microvessels (Figure 4A),
which is similar to the results described for other congestive
cardiomyopathies [4]. These microvascular changes, observed
prior to the onset of significant myocardial degeneration or
fibrosis, were reduced to a minimum by long-term administration
of verapamil [65]. These observations were corroborated by direct
in vivo visualization utilizing a surrogate murine model, i.e., the
cremaster microvascular bed [66]. Direct observation of the effects
of T. cruzi infection on microcirculatory flow in vivo and
quantitative measurement of parameters like velocity of red blood
cell flow (Vrbc) and vessel diameter were provided. When the
cremaster model was examined 20–25 days post-infection in male
CD-1 mice infected with the Brazil strain, a significant decrease in
Vrbc, reversed by verapamil treatment, was observed in the first-
and third-order arterioles and venules. In addition, the marked
inflammatory response attenuated was by verapamil treatment.
The arterioles of the infected mice exhibited segmental areas of
vasospasm and dilatation, possibly the initiating event in
microaneurysm formation (Figure 4B) [67].
The exact mechanism of such vascular lesions has not been fully
clarified. In addition to spastic phenomena, the observation of
platelet thrombi in the coronary microcirculation of infected mice
led to an investigation of the possible mechanisms involved.
Toward this end, a study using A/J mice and human umbilical
vein endothelial cells (HUVECs) infected with the Tulahuen strain
of T. cruzi showed an increased aggregation of platelets during the
early stage, a factor that may contribute to the development of
thrombosis. In addition, increased levels of TXA2 were observed.
This finding could contribute to the increased intravascular
platelet aggregation and focal microvascular spasm [68]. Recently,
Ashton and colleagues [69] demonstrated that all three life forms
of the parasite are capable of synthesizing TXA2, but it was most
dramatic in amastigotes. These observations suggest that TXA2
could contribute to the pathogenesis of CCC and its clinical
manifestations.
Early in the course of infection, parasites are evident in the
coronary microvascular endothelial cells (ECs) before parasit-
emia can be detected, suggesting that the coronary endothelium
could be an initial, if not primary, target of T. cruzi infection.
Acutely infected rats developed changes in the endothelial layer
characterized by EC swelling and a few points of cytoplasmic
discontinuity that appeared as holes exposing the subendothelial
collagen that is usually associated with platelet-fibrin aggregates,
which might affect the generation of vasoactive substances, and
impairs the equilibrium between opposing forces [70]. In vitro
and in vivo studies indicate that infection of the endothelium
r e s u l t si ne x p r e s s i o no fb o t hp r o - i n f l a m m a t o r yc y t o k i n e sa n d
vascular adhesion molecules, which are both important compo-
nents of the inflammatory response [71–73] T. cruzi infection of
ECs was demonstrated to cause activation of the NF-kB
pathway, likely contributing to the induction of cytokine and
adhesion molecular expression in the endothelium [72].
Furthermore, in the myocardium obtained from T. cruzi–infected
humans and experimental animals, increased expression of
cytokines, iNOS, and adhesion molecules has been reported
[73–75].
Endothelial cells are the major source of endothelin 1 (ET-1), a
potent vasoconstrictor, and its role in the pathogenesis of chagasic
heart disease has been demonstrated. The infection of CD1 mice
with the Brazil strain and C57BL/6 mice with the Tulahuen strain
caused an intense vasculitis, high plasma ET-1 levels, and
Figure 1. Micropathology of Chagas heart disease. (A) Acute myocarditis with foci of myocytolytic necrosis and degeneration are seen with an
intense inflammatory infiltrate around ruptured pseudocysts of parasite (arrows, in the inset). Intact intramyocyte parasite nest without inflammatory
response (arrow heads, in the inset). Hematoxylin and eosin staining. Bar=100 mm; inset bar=50 mm. (B) Chronic fibrosing myocarditis. Foci of
myocytolytic necrosis associated with mononuclear inflammatory infiltrate and incipient interstitial fibrosis appearing in light blue (arrows). Gomori
trichrome staining. Bar=100 mm. (C) Chronic fibrosing myocarditis. Predominantly perimysial interstitial fibrosis extending to the endomysium (arrow
heads) appearing in light blue associated with mononuclear inflammatory infiltrate. Gomori trichrome staining. Bar=500 mm. (D) Chronic fibrosing
myocarditis. Interstitial and diffuse fibrosis manifested by increased amount of thick collagen fibers surrounding muscle fiber bundles (perimysial
matrix) and around intramural coronary vessels, combined with a less pronounced increase in the endomysial matrix. Picrosirius red staining.
Bar=500 mm.
doi:10.1371/journal.pntd.0000674.g001
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preproET-1, endothelin converting enzyme (ECE), and ET-1 in
the myocardium [76]. It has been hypothesized that T. cruzi–
derived molecules provoke overexpression of ET-1 [77]. Elevated
levels of plasmatic ET-1 have been demonstrated in patients with
CCC [78]. To further test the hypothesis that ET-1 contributes to
the pathogenesis of murine chagasic cardiomyopathy, mice with a
deletion of the gene for ET-1 in either cardiomyocytes or ECs
were used to distinguish between ET-1 derived from both cell
types. In infected mice in which the gene for ET-1 was deleted in
cardiomyocytes, there was a reduction in myocardial inflammation
and fibrosis [79]. In addition, these mice displayed a reduction in
cardiac enlargement as revealed by cardiac magnetic resonance
imaging and echocardiography. This data provided further
evidence of a role for ET-1, particularly myocyte-derived ET-1,
in the pathogenesis of CCC.
Figure 2. Gross pathology of chronic Chagas cardiomyopathy (four-chamber frontal view). (A) Cardiomegaly with a left apical aneurysm
(arrow). Myocardium hypertrophy. Marked thinning can be noted in the obtuse border of the heart at the submitral area (arrow head). At the apex of
the right ventricle, distinct replacement of myocardial tissue by adipose tissue can be seen. (B) Cardiomegaly. Thinning and thrombosis at apices of
both ventricles (arrow heads). Dilatation of cardiac ventricular chambers, mainly the right one. Fibrofatty substitution at the apex of the left ventricle
and major part of the right ventricular free wall. (C) Normal-sized heart showing an enormous aneurysm at the apex of the left ventricle. Hypertrophy
of the right ventricle free wall except for a marked thinned apex can be clearly seen. (D) Mildly enlarged heart showing dilatation of the four
chambers. Giant left apical aneurysm. Thinning of left border of the heart immediately below the mitral valve. (E) Globally enlarged chronic chagasic
heart with dilatation mainly affecting the right-sided chambers. Adipose replacement of the right ventricular myocardium, particularly at the apical
region, associated with bulging can be seen (arrow heads). (F) Transillumination of a chagasic heart showing thinning of the muscle wall ‘‘cor
bifidum’’ with aneurysm at the left apex (arrow heads), and marked thinning of the anteroapical region of the right ventricle. RV, right ventricle; LF,
left ventricle. All bars=3 cm.
doi:10.1371/journal.pntd.0000674.g002
www.plosntds.org 6 August 2010 | Volume 4 | Issue 8 | e674Figure 3. Study in mice chronically infected with T. cruzi demonstrating involvement of microcirculation. (A) Enlarged heart of a mouse
infected with T. cruzi 100 days post-infection showing marked thinning of the apex of the left ventricle (apical aneurism). Bar=2 mm. (B) Myocardium
of an infected mouse stained by the Carstairs method for demonstration of platelets. An occlusive platelet thrombus is seen in a small epicardial
vessel (arrowhead). Bar=50 mm. Mononuclear cell infiltration, interstitial edema and fibrosis, and foci of myocytolytic necrosis. (C) Schematic
representation of coronal sections through mice hearts infected with T. cruzi 100 days post-infection without (upper panel) and with (lower panel)
apical aneurism, showing the extent of foci of myocytolytic necrosis. These areas are scattered throughout the ventricular and atrial myocardium, but
are more numerous in the subendocardial and subepicardial regions in the apex, papillary muscles, and base of the ventricles. (D) Electron
micrograph showing complete dissolution of myofibrils within a myofiber (*) of an infected mouse with characteristic myocytolysis or myocytolytic
necrosis. Bar=10 mm.
doi:10.1371/journal.pntd.0000674.g003
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after intraperitoneal inoculation with trypomastigote forms of the
12SF strain of T. cruzi/kg body weight were studied. This study
demonstrated that myocarditis characterized by small focal areas
of lesion and myocytic necrosis associated with interstitial
mononuclear infiltration. Ultrastructurally, degenerative changes
were observed in ECs in contact with T lymphocytes, as well as
platelet aggregates and fibrin thrombi in the intramyocardial
capillaries. These alterations suggested that a possible interaction
between ECs and effector immune cells might play an important
role in the pathogenesis of the myocellular lesion and of the
microangiopathy observed in this model [80].
In vitro studies. Direct infection of human endothelial
cells in culture with T. cruzi resulted in the alteration of various
critical biochemical processes responsible for the maintenance of
microvascular perfusion, such as Ca
2+ homeostasis and generation
of inositol trisphosphate and prostaglandin I2 [81,82]. T. cruzi
infection of HUVECs results in an alteration of cyclic AMP
metabolism, which plays a protective role against the direct and/
or indirect lesion caused by the adhesion and aggregation of
circulating platelets to ECs [83]. However, inflammatory cells may
contribute to a state of microvascular hypoperfusion by secreting
cytokines and other factors known to affect platelets and ECs.
Cytokines contribute to the pathogenesis of various parasitic
infections, and their roles in the pathogenesis of T. cruzi infection
have been extensively studied. The increase of interleukin-1b (IL-
1b), IL-6, and colony stimulating factor 1 (CSF-1) in infected ECs
may lead to alterations in their function [83]. IL-1b is elaborated
by activated macrophages and by peripheral blood mononuclear
cells, including those infected with T. cruzi, and by a variety of
other cell types, such as ECs [84,85]. The antithrombotic
properties of ECs may be altered by IL-1b. This cytokine may
reduce tissue production of the plasminogen activator and increase
production of the inhibitor of this activator, an event that may
result in thrombus formation [86,87]. Although the products of IL-
6 are markedly increased in EC cultures, it has not been possible to
determine whether non-infected cells are also induced to produce
this cytokine. Since IL-1b may induce IL-6 production by ECs, it
is not clear whether IL-6 production by infected cells is a direct
result of the infection or is induced by the IL-1b produced in
response to infection. CSF-1 is an important growth factor for the
proliferation and maturation of cells of the mononuclear lineage
[85]. It is also important in recruitment, possibly acting in
conjunction with IL-1b. High CSF-1 levels have been detected in
cultured ECs infected with T. cruzi. These observations may reflect
the growth of the monocyte population in the microvasculature,
resulting in the later elaboration of proinflammatory cytokines
[71]. In addition, trypomastigotes may elaborate a neuraminidase
that may be involved in the removal of sialic acid from the surface
of mammalian myocardial cells and ECs, facilitating thrombin
binding. The loss of this endothelial surface protector molecule
may contribute to platelet aggregation and thrombosis within the
small coronary vessels [88]. These factors acting together may
ultimately result in spasm and thrombosis in the small coronary
vessels, inducing focal myocardial damage.
The consequences of T. cruzi infection of HUVECs with regard
to the production of biologically active ET-1 are an increased
expression of ET-1 mRNA [89]. Increased production of ET-1
may contribute to the coronary microvascular vasoconstriction
previously reported in experimental Chagas disease [9].
Studies in humans. Anatomical studies have shown
structural derangement and rarefied microvasculature in the left
ventricular myocardium. A histotopographical study comparing
the microcirculatory system after injection of an opaque medium
into chagasic and control human hearts demonstrated focal
decapillarization in chronic Chagas disease due to extraluminal
compression, suggesting that this might be the cause of focal
myocytolytic necrosis [90]. Similarly, a postmortem radiological
study of chagasic hearts revealed vascular changes at the heart
apex characterized by distorted and/or scarce vessels associated
with decreased arterial density, presumably related to the
pathogenesis of apical aneurysm [91].
The evaluation of chest pain is a major problem in chagasic
patients. Almost all exhibit symptoms that are atypical for classic
angina pectoris. Although symptoms suggestive of myocardial
ischemia are present, coronary angiographical studies show
normal or nearly normal coronary arteries in more than 90% of
patients studied [92]. This peculiarity had been previously
reported in a postmortem study [93]. However, patients
specifically selected on the basis of chest pain did show perfusion
abnormalities detectable by thallium-201 scintigraphy, suggesting
that myocardial ischemia, possibly of the microvascular type, may
contribute to the genesis of the symptoms (Figure 4C).
Abnormal perfusion in different groups of chagasic patients has
been confirmed by various independent investigators using
isonitrile-99m-technetium [94] or thallium-201 [92,95]. In
addition, myocardial capillary blood flow in chronic chagasic
patients with no significant clinical or electrocardiographic
manifestations proved to be markedly reduced when evaluated
Figure 4. Changes of coronary perfusion in experimental T.
cruzi infection and human chronic Chagas cardiomyopathy. (A)
Microfil injection of the coronary vasculature of A/J mice infected with
T. cruzi 15–17 days post-infection. Section of the atrium reveals saccular
microaneurysms and vasospasm in the subendocardium. (B) Videomi-
crographs of representative fields of the microvasculature obtained
from the cremaster muscle from T. cruzi–infected mice 20–25 days post-
infection (a, arterioles; v, venules). Upper left and right panels:
Representative fields showing areas of vasospasm (arrows). Left lower
panel: In this field there is an area of segmental microvascular dilation
(arrow). Right lower panel: Infected mouse treated with verapamil in
which there were no areas of vasospasm or dilatation. Bar=20 mm
(from Tanowitz et al. (1996) Journal of Parasitology 82: 124–130, with
permission of Allen Press and the Journal). (C) Planar images (anterior,
left anterior oblique, and lateral views of myocardial scintigraphy with
Tc-labelled microspheres in a chronic chagasic patient whose complaint
was chest pain, but who had angiographycally normal coronary arteries.
A prominent perfusion defect is seen in the anterolateral and
posterolateral regions of the left ventricle. Courtesy of J. Antonio
Marin-Neto, MD.
doi:10.1371/journal.pntd.0000674.g004
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normal. The reduction observed, comparable to that exhibited by
a group of non-chagasic patients with obstructive coronary disease,
occurred under basal conditions [96] and, to a lesser extent,
during exercise [97]. Using a specific marker of regional flow
independent of cell metabolic activity, a perfusion defect was
detected in 55% of the 18 chagasic patients with CCC and
essentially normal epicardial coronary circulation [98].
Vasospastic mechanisms have been proposed in the genesis of
coronary accidents in patients with CCC [99]. For example, it was
demonstrated that cardiopathic chagasic patients present an
abnormal, endothelium-dependent, coronary vasodilating mecha-
nism as demonstrated by acetylcholine and adenosine infusion into
the left coronary artery, suggesting that epicardial and microvas-
cular coronary reactivity may be altered in these patients. The
clinical importance of this alteration awaits elucidation. However,
this abnormality of the coronary microvasculature may contribute
to the genesis of the symptoms related to the ischemic processes
observed in chronic chagasic patients and to acute myocardial
infarction in the absence of significant coronary damage [100].
Biopsies obtained from chronic chagasic hearts revealed a
marked thickening of the basement membrane in most myocytes
and capillaries (up to 20 times the normal thickness) [101]. This
alteration is similar to the thickening with or without multiple
layers reported for the basement membranes of myocardial
capillaries in other cardiomyopathies [102]. A very well-developed
capillary network has been observed in chagasic human hearts
using a cell-maceration scanning electron microscopic method
[103]. This alteration may represent the probable cause of slow
capillary flow, contributing to the hypoxic changes observed in
CCC.
Significant dilatations of arterioles and capillaries in various
ventricular areas of chagasic hearts compared to hearts with
dilated cardiomyopathy were described. It was hypothesized that
such microcirculatory dilatations could cause inadequate blood
flow distribution in the watershed area lying between the two main
coronary flow sources (the anterior descending and posterior
descending arteries, and the right and circumflex coronary
arteries), resulting in ischemic and extensive fibrosis within the
left ventricle apical and posterior regions [104].
The relation of regional sympathetic denervation and myocar-
dial perfusion disturbance to wall motion impairment was
described in patients with CCC. Global left ventricular function,
segmental wall motion analysis, and myocardial perfusion were
evaluated in 58 patients, demonstrating myocardial perfusion
defects in the absence of epicardial coronary artery disease. In
addition, the extension and severity of perfusion abnormalities
parallel the progression of myocardial damage. These results
support the notion that perfusion disturbance in CCC may be
caused by transient disturbances of coronary blood flow regulation
at the microvascular level [105]. The same group correlated the
clinical, electrocardiographic, angiographic, electrophysiologic,
and wall motion/myocardial perfusion disturbances in chronic
chagasic patients with either sustained or non-sustained ventricular
tachycardia. The fact that both fixed perfusion defects (reflecting
local fibrosis) and reversible and paradoxical defects predominate
in the dyssynergic arrhythmogenic left ventricle region is also
compatible with the hypothesis that microvascular ischemia plays
an important role. Thus, several findings suggest that transient
disturbances of coronary blood flow regulation at the microvas-
cular level may be a causative mechanism of regional myocardial
degeneration, with a consequent reparative fibrosis that ultimately
constitutes the substrate for reentrant circuits and the appearance
of both sustained and non-sustained ventricular tachycardia [106].
Chronic Chagas Heart Disease and the Interstitial Matrix
In CCC there is extensive damage of the myocardium and,
consequently, it is not surprising that interstitial fibrosis is one of
the most prominent features [38]. Since the extracellular matrix
has an important role in the structure and function of the
myocardium [107–109], the progressive accumulation of intersti-
tial collagen could well be the main factor responsible for the
progressive impairment of the contractile performance of the
myocardium and for the increase in arrhythmogenic risk in
chronic Chagas heart disease.
The pattern of myocardial fibrosis in chronic Chagas heart
disease probably reflects the pathogenic mechanisms involved.
Diffuse foci of myocardial myonecrosis may be the main etiology
factor of the chronic expression in chronic chagasic cardiomyop-
athy [110]. The presence of infiltrates of lymphomononuclear cells
is a consistent and prominent finding in the chronic chagasic
fibrosing myocarditis. Our results clearly showed the colocaliza-
tion of the fibrosed areas and fibroblasts with T lymphocytes and
macrophages. T lymphocytes have been demonstrated to play a
role in the pathogenesis of fibrosis. Bleomycin-induced pulmonary
fibrosis in mice is attenuated by depletion of CD4
+ or CD8
+ T cells
and completely abrogated by total T cell depletion [111]. CD4
+
and CD8
+ cells may act directly on mesenchymal cells by means of
cytokine production that leads to the proliferation of fibroblasts
and the synthesis of collagen or indirectly by enhancing the
activation of macrophages [111]. Macrophages, when activated by
cytokines, have been shown to produce powerful inducers of
fibrosis, such as transforming growth factor b (TGF-b) and
platelet-derived growth factor (PDGF) [112,113]. Our study shows
a predominance of T cells and macrophages concentration.
Besides, since myocytes can produce growth factors such as
fibroblast growth factor [114], the injured myocytes could
potentially produce and release such factors, contributing to
fibrogenesis. In addition, increased production of ET-1 by cardiac
myocytes correlates closely with the degree of hemodynamic and
functional impairment [76,115], indicating that this peptide could
also contribute to myocardial fibrosis through its collagen
synthesis-enhancing effect [116].
Studies on Therapeutic Strategies
Increasing evidence for abnormalities at the microvascular level
has been accumulated from studies both in chagasic patients and
experimentally infected animals. The changes suggest that
myocardial lesions develop, at least in part, as a consequence of
additive and progressive cell necrosis initiated and perpetuated by
changes in myocardial microcirculation. Based on these studies, it
is possible to speculate that therapy aimed at decreasing the degree
of microvascular ischemia could prevent or ameliorate myocardial
damage, ventricular dysfunction, and ventricular arrhythmias.
Angiotensin-converting enzyme inhibitors (ACEIs) have
emerged as the treatment of choice for patients with all degrees
of heart failure, ranging from asymptomatic left ventricular
dysfunction to severe heart failure. The mechanism of action of
captopril, an ACEI, involves suppression of angiotensin II, a
potent vasoconstrictor, and increased levels of bradykinin through
the inhibition of kininase II, which induces NO release in ECs and
stimulates the production of prostacyclin, a vasodilating prosta-
glandin [117]. Captopril is commonly given to patients with CCC.
Despite routine administration of captopril to patients with CCC,
few studies have examined the effects of this drug in these
individuals. Captopril has been shown to improve cardiac function
with few side effects [118,119] but has not been found to reduce
mortality [120]. In a study using A/J mice infected with a Brazil
strain of T. cruzi, the animals developed acute myocarditis 21 days
www.plosntds.org 9 August 2010 | Volume 4 | Issue 8 | e674after infection, characterized by severe focal inflammation,
necrosis, and fibrosis. The administration of captopril significantly
reduced necrosis and fibrosis in infected mice. Taken together,
these results suggest that captopril can reduce myocarditis and
fibrosis in T. cruzi infection.
The effect of enalapril, another ACEI, on ventricular function
in patients with CCC has been evaluated. A significant
improvement of diastolic function and a trend to improvement
of systolic function was seen in the group that received digitalics,
diuretics, and enalapril in comparison with the group that received
digitalics and diuretics only. This beneficial action of enalapril in
diastolic function could be related to decreased venous return and
increased arteriolar vasodilatation [121].
Two cases of myocarditis due to acute Chagas disease, resulting
from oral intake of sugar cane juice infected with T. cruzi,
developed acute decompensated NYHA class IV heart failure.
Both patients were refractory to treatment with ACEI, aldosterone
antagonists, and dobutamine. Levosimendan was prescribed, and
clinical improvement was observed, with progression to NYHA
class II. Levosimendan is a positive inotropic drug with
vasodilatory properties with anti-ischemic action through in-
creased coronary flow and reduced preload and afterload. The
limitations of this study include lack of studies with a placebo
group to ensure that the benefits are a result of the drug and not
side effects of other medications [122].
Further evidence of the microvascular involvement in CCC
pathogenesis has been demonstrated by studies with verapamil, a
first generation L-type calcium channel antagonist [123]. T. cruzi–
infected CD1 mice given verapamil immediately after infection
showed decreased mortality and attenuated myocardial inflam-
mation and fibrosis [65,67]. However, when verapamil was
administered after 60 days post-infection, there was no ameliora-
tion of infection-associated structural and functional abnormalities.
The results suggested that verapamil acts early in the course of T.
cruzi infection to prevent ventricular dilatation and myocardial
dysfunction [124]. Verapamil has several well-known actions that
may reduce the severity of cardiomyopathy, including increasing
coronary blood flow, inhibition of calcium channels and a and b-
adrenergic activity, and platelet aggregation [123].
Phosphoramidon, a potent inhibitor of endothelin-converting
enzyme, reduced myocardium inflammation and fibrosis and
attenuated right ventricle diameter increase in CD1 mice infected
with the Brazil strain of T. cruzi and treated for the initial 15 days
post-infection [125].
Conclusions
The pathogenesis of chronic chagasic cardiomyopathy, which
takes decades to develop after the initial infection with T. cruzi,
occurs as a consequence of several physiopathological processes.
The very rare finding of parasites in the myocardium in the
chronic phase of the disease is out of proportion to the degree of
organ compromise and dysfunction. The chronic fibrosing
myocarditis development is related to progressive and additive
focal cellular necrosis and associated with inflammatory mononu-
clear infiltrate and reactive and reparative interstitial fibrosis and
surrounding myocytes hypertrophy. Based on the evidence
presented in the present review, these processes may be initiated
and perpetuated by alterations in the myocardial microcirculation.
The intrinsic and/or extrinsic cardiac necrosis system abnormal-
ities and immunological mechanisms may contribute, but there
has been extensive debate on their significance on the marked
cardiac damage.
The treatment of the chronic Chagas heart disease has relied on
the same conventional treatments for other cardiomyopathies. The
studies cited illustrate the potential benefit of therapeutics aimed at
the underlying pathophysiological microvascular mechanism of
CCC. However, the favorable effect of these changes has not yet
been established due to the lack of randomized multicenter clinical
trials using different treatments to determine their impact on
clinical improvement and survival of chronic chagasic patients.
There is an urgent need for developing adequate specific
treatment procedures, particularly during the chronic phase of
the disease.
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